Skip to content

Cosmetic & Topical

PTD-DBM

Research peptide that releases a brake on Wnt signaling to reawaken hair follicles; promising in mice, unproven in people.

InvestigationalEvidence level 2 of 5: Animal data, minimal humanAlso: Protein transduction domain–Dishevelled binding motif, CXXC5–Dvl disrupting peptide

Overview

PTD-DBM was designed by Korean researchers who found that a protein called CXXC5 is elevated in balding scalp and acts as a brake on Wnt/β-catenin signaling, the pathway that tells hair follicles to grow and regenerate. The peptide carries a cell-penetrating segment fused to a short sequence that blocks CXXC5 from binding Dishevelled, a key Wnt relay protein. In mouse models, topical PTD-DBM — particularly combined with valproic acid — accelerated hair regrowth and even stimulated new follicle formation in wounded skin. Human data are limited to laboratory tissue work and informal use. It is best viewed as an experimental adjunct to proven treatments like minoxidil and finasteride, not a replacement.

Classification
Synthetic cell-penetrating peptide (protein-transduction domain fused to a Dishevelled-binding motif)
Route
Topical (scalp), often with microneedling
Half-life
Not well established

Mechanism of action

Primary targetCXXC5–Dishevelled interaction (Wnt/β-catenin pathway)
  1. Cell penetrationPTD segment carries the peptide across follicle cell membranes.
  2. CXXC5 displacementDBM motif blocks CXXC5 binding to the Dishevelled protein.
  3. Wnt signal releaseDishevelled resumes relaying Wnt signals; β-catenin stabilizes.
  4. β-catenin gene activationNuclear β-catenin activates follicle growth and stem-cell genes.
  5. Anagen entryDermal papilla and bulge cells push follicles into growth phase.
Downstream effects
  • Hair regrowth
  • Follicle neogenesis (mice)
  • Improved wound healing

Researched for

  • Androgenetic alopecia
  • Wound-induced hair neogenesis
  • Skin wound healing and scarring

Research notes

  • Lee et al. (J Invest Dermatol, 2017): CXXC5 elevated in human balding scalp; PTD-DBM with valproic acid restored hair growth in mice.
  • Follow-up work showed wound-induced hair neogenesis and reduced scarring in mouse skin.
  • No peer-reviewed human efficacy trials; dose, formulation and long-term safety in humans are unknown.
  • Wnt pathway activation carries a theoretical proliferative risk that has not been studied long-term.

Reported side effects

  • Scalp irritation or redness
  • Contact dermatitis
  • Unknown long-term effects (limited data)

Contraindications & cautions

  • Active scalp dermatitis or open wounds
  • History of skin cancer in treated area
  • Pregnancy and breastfeeding
  • Known hypersensitivity to formulation

Lab monitoring

  • Ferritin and iron panel
  • Zinc, vitamin D
  • Thyroid panel (TSH, free T4/T3, antibodies)
  • Total/free testosterone, DHT if androgenic alopecia suspected
  • Scalp photography and dermoscopy

Dosing and pricing for PTD-DBM

Dosing references and compound pricing are available to established patients in the secure portal after a medical evaluation.

Ready to take control of your health?

Start with a 60-minute physician evaluation, virtually in seven states or in person in Reston, Virginia.

Request a consultation 703-400-5314

Cash-pay. HSA and FSA accepted. Monday–Friday, 10 AM – 2 PM (virtual and in person).